Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 16Carcinoma, Renal Cell 14Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Neoplasms 6Carcinoma, Medullary 6Thyroid Neoplasms 5Melanoma 5Breast Neoplasms 5Ovarian Neoplasms 4Neuroendocrine Tumors 4Carcinoma, Transitional Cell 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Kidney Neoplasms 3Adenocarcinoma, Follicular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Pain 2Osteosarcoma 2Multiple Myeloma 2

Interventions

Gemcitabine 7Cisplatin 5Ramucirumab 3Platinum 3Paclitaxel 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3pembrolizumab 2Carboplatin 2rucaparib 1pegfilgrastim 1pazopanib 1eribulin 1enzalutamide 1enfortumab vedotin 1dehydroftorafur 1cabozantinib 1avelumab 1atezolizumab 1aflibercept 1Taxes 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Mitozytrex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urethral Neoplasms × cabozantinib × Clear all
NCT01688999 2022-10-18

Cabozantinib for Advanced Urothelial Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
69 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡